1. Home
  2. FCBC vs SGMT Comparison

FCBC vs SGMT Comparison

Compare FCBC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Community Bankshares Inc. (VA)

FCBC

First Community Bankshares Inc. (VA)

HOLD

Current Price

$47.58

Market Cap

888.3M

Sector

Finance

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

SELL

Current Price

$9.64

Market Cap

761.6M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
FCBC
SGMT
Founded
1874
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
888.3M
761.6M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
FCBC
SGMT
Price
$47.58
$9.64
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
★ $27.91
AVG Volume (30 Days)
112.1K
★ 1.1M
Earning Date
10-27-2026
11-16-2026
Dividend Yield
★ 4.97%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 1.82
N/A
Revenue
N/A
★ $2,000,000.00
Revenue This Year
$15.08
N/A
Revenue Next Year
$24.39
N/A
P/E Ratio
$25.65
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.21
$4.50
52 Week High
$50.17
$11.45

Technical Indicators

Market Signals
Indicator
FCBC
SGMT
Relative Strength Index (RSI) 42.67 53.33
Support Level $46.31 $8.54
Resistance Level $49.64 $11.33
Average True Range (ATR) 1.42 0.62
MACD -0.19 0.11
Stochastic Oscillator 18.51 71.30

Price Performance

Historical Comparison
FCBC
SGMT

About FCBC First Community Bankshares Inc. (VA)

First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: